Results 51 to 60 of about 15,139,370 (299)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors

open access: yesChinese Journal of Lung Cancer, 2019
Immunotherapy for malignant tumors is a hot spot in current research and treatment of cancer. The activation of programmed cell death receptor-1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA)-4 relevant signaling pathway can inhibit the ...
Yue LI   +9 more
doaj   +1 more source

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors

open access: yesZhongliu Fangzhi Yanjiu, 2021
In recent years, tumor immunotherapy with immune checkpoint as the target has attracted much attention because of its remarkable efficacy. However, with the application of immune-checkpoint inhibitors (ICIs), more and more immune-related adverse events ...
LI Ying, YIN Haoyuan, PAN Li, FENG Lei
doaj   +1 more source

The human gut microbiome across the life course

open access: yesFEBS Letters, EarlyView.
Despite significant individual variation and continuous change throughout life, the human gut microbiome follows some life stage‐specific trends. This article provides a brief overview of how gut microbiome composition shifts across different phases of life. Created in BioRender. Özkurt, E. (2026) https://BioRender.com/8q4nrnc.
Alise J. Ponsero   +4 more
wiley   +1 more source

Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis

open access: yesCancer Medicine
Background Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with ...
Jing Lei   +7 more
doaj   +1 more source

Predictors of Immunotherapy-Induced Immune-Related Adverse Events [PDF]

open access: yesCurrent Oncology, 2018
Purpose: We aimed to elucidate predictive factors for the development of immune-related adverse events (iraes) in patients receiving immunotherapies for the management of advanced solid cancers. Methods: This retrospective study involved all patients with histologically confirmed metastatic or inoperable melanoma, non-small-cell lung cancer, or renal ...
Kartolo, A.   +4 more
openaire   +2 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Management of immune checkpoint inhibitor‐related rheumatic adverse events

open access: yesThoracic Cancer, 2020
Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients ...
Jiaxin Zhou   +10 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Management of immune checkpoint inhibitor‐related dermatologic adverse events

open access: yesThoracic Cancer, 2020
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment.
Xiaoyan Si   +10 more
doaj   +1 more source

Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. [PDF]

open access: yes, 2014
Few data describe antiretroviral treatment (ART)-related adverse events when treatment is initiated at CD4 cell counts more than 350 cells/μl.
Chadwick, D   +31 more
core   +1 more source

Home - About - Disclaimer - Privacy